Diastolic heart failure and its correction in patients with type 2 diabetes mellitus with arterial hypertension

In recent years the results of specially designed studies assessing the cardiovascular (CV) -safety of antidiabetic drugs from the groups of dipeptidyl peptidase-4 (DPP4) inhibitors, glucagon-like preptide-1 (GLP-1) receptor agonists and sodium – glucose co-transporter-2 (SGLT2) inhibitors have become known. SGLT2 demonstrated not only the efficacy and CV-safety of the drug in the form of a decrease in CV mortality by 38%, but also a decrease in hospitalizations for HF by 35%. Further studies with SGLT2 inhibitors confirmed positive effect on HF, indicating a class effect of the drugs. They have advantages of using for the primary and secondary prevention of HF.